

Research Article

Mast Cells Exert Anti-Inflammatory Effects in an IL10^{-/-} Model of Spontaneous Colitis

E. M. Lennon ¹, L. B. Borst,² L. L. Edwards,² and A. J. Moeser ³

¹Department of Small Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN 37996, USA

²Department of Population Health and Pathobiology, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27607, USA

³Gastrointestinal Stress Biology Laboratory, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA

Correspondence should be addressed to A. J. Moeser; moeserad@msu.edu

Received 7 November 2017; Revised 27 February 2018; Accepted 4 March 2018; Published 17 April 2018

Academic Editor: Alex Kleinjan

Copyright © 2018 E. M. Lennon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mast cells are well established as divergent modulators of inflammation and immunosuppression, but their role in inflammatory bowel disease (IBD) remains to be fully defined. While previous studies have demonstrated a proinflammatory role for mast cells in acute models of chemical colitis, more recent investigations have shown that mast cell deficiency can exacerbate inflammation in spontaneous colitis models, thus suggesting a potential anti-inflammatory role of mast cells in IBD. Here, we tested the hypothesis that in chronic, spontaneous colitis, mast cells are protective. We compared colitis and intestinal barrier function in IL10^{-/-} mice to mast cell deficient/IL10^{-/-} (double knockout (DKO): Kit^{Wsh/Wsh} × IL10^{-/-}) mice. Compared with IL10^{-/-} mice, DKO mice exhibited more severe colitis as assessed by increased colitis scores, mucosal hypertrophy, intestinal permeability, and colonic cytokine production. PCR array analyses demonstrated enhanced expression of numerous cytokine and chemokine genes and downregulation of anti-inflammatory genes (e.g., *Tgfb2*, *Bmp2*, *Bmp4*, *Bmp6*, and *Bmp7*) in the colonic mucosa of DKO mice. Systemic reconstitution of DKO mice with bone marrow-derived mast cells resulted in significant amelioration of IL10^{-/-}-mediated colitis and intestinal barrier injury. Together, the results presented here demonstrate that mast cells exert anti-inflammatory properties in an established model of chronic, spontaneous IBD. Given the previously established proinflammatory role of mast cells in acute chemical colitis models, the present findings provide new insight into the divergent roles of mast cells in modulating inflammation during different stages of colitis. Further investigation of the mechanism of the anti-inflammatory role of the mast cells may elucidate novel therapies.

1. Introduction

IBD is an incurable, debilitating intestinal disease, and treatment often consists of lifelong systemic immunosuppression [1–3]. The pathogenesis of IBD is complex and is thought to result from a combined effect of genetic predisposition, intestinal epithelial barrier dysfunction, alterations in the intestinal microbiota, and immune dysregulation [4–7]. The adaptive immune system has been the focus of IBD research for years; more recently, research from genome-wide association studies and other immunological research has highlighted the critical role of the innate immune system [8–11]. Mast cells are innate immune cells, which are well-known for their

proinflammatory roles in conditions such as allergy/anaphylaxis and asthma [12–14]. Several lines of evidence have implicated mast cells in the pathophysiology of IBD as they are found to be increased in number and exhibit a degranulated appearance in patients with Crohn's disease and ulcerative colitis [15–24]. Additionally, IBD patients demonstrate increased mast cell mediator release upon stimulation compared to controls [25–28] and have increased levels of a histamine metabolite in their urine [29]. In line with the role of mast cells in inflammatory conditions such as allergy and asthma, mast cells have been proposed to be major drivers of intestinal inflammation through various mechanisms [30–34]. However, studies investigating the role of mast cells

in animal models of colitis have been conflicting. In chemical colitis models such as dextran sodium sulfate- (DSS-) and trinitrobenzene sulfonic acid- (TNBS-) induced colitis, genetic mast cell deficiency or pharmacologic inhibition of mast cells ameliorated colitis [30, 35–41], while in another, mast cell deficiency had no effect on colitis [42]. In addition, mast cell proteases increase in serum and tissue in response to DSS colitis in mice [35], and it was shown that mast cell protease-6-deficient mice exhibit dampened DSS and TNBS colitis [30]. Pharmacological mast cell stabilization (ketotifen) and tryptase and chymase inhibition (nafamostat and NK3201, resp.) decrease mucosal damage in TNBS colitis [37–40].

Together, there is strong evidence supporting a deleterious (proinflammatory) role for mast cells in acute or subacute chemical colitis. However, there are a number of studies indicating that mast cells may also play beneficial roles. For example, in a DSS colitis model in rats, an increase in mast cell numbers and mast cell protease II was observed during the resolution phases of intestinal inflammatory and histological lesions, suggesting that mast cells might play a beneficial role in the chronic or recovery phase of colitis [43]. In another study in DSS colitis, mast cell-deficient mice had delayed recovery compared to their wild-type counterparts [44]. In addition, compared with IL10-deficient mice, IL10-deficient/mast cell-deficient double-knockout mice (DKO mice) exhibit increased colitis and associated colonic pathophysiology indicating that in spontaneous colitis models, mast cells may be protective [45, 46].

While well-known for their proinflammatory properties, it has become increasingly evident that mast cells can have potent anti-inflammatory or immunosuppressive effects either via direct or indirect mechanisms in certain disease conditions [47, 48]. Mast cells have been shown to promote tolerance through induction of regulatory T cells and influence dendritic cells [49–53]. Mast cell tryptase, a serine protease, has been shown to degrade cytokines and matrix metalloproteinases and aids in bacterial defense [54]. Additionally, mast cells are important for tissue healing [55].

Mast cells mediate their functional role in homeostasis and in disease through the release of granule-associated preformed mediators (e.g., histamine, proteases, and TNF) as well as de novo-synthesized cytokines, chemokine, and lipid-derived mediators [48, 56–58]. Mast cell mediators can have diverse effects on numerous cell types and tissues including permeability of epithelial and endothelial barriers, immune cell recruitment and pathogen defense, nerve activation and sensitization, secretion, motility, and blood flow [33, 59–70].

Although deleterious in chemical colitis, mast cells may have a different effect in other colitis models that more closely replicate human IBD, for example, the IL10^{-/-} mouse. A severe form of childhood-onset IBD results from polymorphisms in the IL10 gene or that of the IL10 receptor [71–74], which is a similar pathogenesis to the IL10^{-/-} mouse. While it has been shown that mast cell deficiency enhanced spontaneous colitis in the IL10^{-/-} murine model [45, 46], the precise role for mast cells in spontaneous colitis has yet to be fully determined. Utilizing mast cell-deficient × IL10-deficient

(DKO) murine model of spontaneous colitis, combined with systemic mast cell engraftment approaches, the objective of this study was to define the role of the mast cell in spontaneous colitis.

2. Materials and Methods

2.1. Experimental Groups. IL10^{-/-} mice on a C57Bl/6 background (IL10^{-/-}) and IL10^{-/-} × Kit^{Wsh/Wsh} double-knockout (DKO) mice that lack mast cells in addition to IL10 (C57Bl/6 background) were used in this study. Mice were housed in a barrier facility under specific pathogen-free conditions. Among others, murine parvovirus, norovirus, and *Helicobacter* were excluded from this facility. Groups of DKO mice were reconstituted with bone marrow-derived mast cells at 4 weeks of age as previously described. Tissue collection was performed at 20–24 weeks of age [75]. Roughly equal (within $n = 2$) numbers of male and female mice were used in each experiment. Mice were killed by CO₂ inhalation at 20–24 weeks of age.

2.2. Differentiation and Reconstitution of Bone Marrow-Derived Mast Cells. Bone marrow-derived mast cells (BMMCs) were generated as previously described [75]. Briefly, cells were collected immediately postmortem by flushing bone marrow from the femur of mice. These cells were cultured in the presence of IL3 (5 ng/ml) and stem cell factor (5 ng/ml) (R&D Systems) for 8 weeks with weekly culture media changes. Mast cell purity was assessed by toluidine blue staining and confirmed by performing staining for c-kit and FcεR1 with analysis by flow cytometry, which is typically >98% in our laboratory using these procedures. DKO mice were reconstituted with BMMCs at 4 weeks of age by intraperitoneal injection of 1×10^7 cells as previously described [75]. Mast cell reconstitution was performed with BMMCs derived from both wild-type and IL10^{-/-} mice to demonstrate whether the anti-inflammatory activity of the mast cell is dependent on IL10. Successful reconstitution was confirmed histologically at the time of tissue collection (16–20 weeks following reconstitution) by microscopic examination of toluidine blue-stained sections of the intestine (Figure 1). Reconstituted mice that did not have identifiable mast cells within any section of the colon were excluded from analysis.

2.3. Colitis Scoring. Colonic tissue sections were fixed in 10% buffered formalin and embedded in paraffin, and 4 μm-thick sections were stained with hematoxylin and eosin using standard techniques. Spontaneous colitis scoring was adapted from the criteria reported by Berg et al., as previously described [76]. Five sections of hematoxylin/eosin-stained intestine were examined using a clinical light microscope (Olympus BX45), equipped with a high-resolution digital camera (Olympus DP2-BSW, version 2.2), and scored on a scale from 0–4 by a single-blinded veterinary pathologist (LBB). Mucosal (epithelial) hypertrophy was assessed by measuring the colonic epithelial thickness in micrometers. Well-oriented crypts from 5




FIGURE 1: Inflammation is exacerbated in the absence of mast cells and prevented by reconstitution with bone marrow-derived mast cells. Representative H&E-stained paraffin sections of the colon of 14-to-16-week-old wild-type C57Bl/6 (a), $IL10^{-/-}$ (b), mast cell-deficient colitis prone double knockout (DKO) (c), and DKO mice reconstituted with wild-type mast cells (DKO-rMC) (d). Colitis scores (e) and colonic mucosal height (f) are higher in DKO mice compared to $IL10^{-/-}$, and mast cell reconstitution restores the colitis to the level of $IL10^{-/-}$ mice. Toluidine blue-stained sections confirming the reconstitution of tissue MCs (arrows) (g). WT: $n = 5$; $IL10^{-/-}$: $n = 25$; DKO: $n = 25$; DKO-rMC: $n = 13$. ***, ### $p < 0.001$; * $p < 0.05$, ** $p < 0.01$ versus DKO.

separate colon sections per mouse and 6 randomly selected mucosal areas within each section were measured from the basement membrane of the crypt base to the

mucosal section using the line tool and the 20x objective. The histological scoring criteria are provided in Supplementary Materials.

2.4. Assessment of Intestinal Barrier Function

2.4.1. Ussing Chambers. Segments of the jejunum and proximal colon were harvested and immediately placed in oxygenated (95% O₂ to 5% CO₂) Ringer solution. Tissues were then mounted in 0.3 cm² aperture Ussing chambers (Physiologic Instruments Inc., San Diego, CA) as described previously [77]. Mucosal-to-serosal flux of FITC-dextran (4 kDa; Sigma-Aldrich, St. Louis, MO) (FD4) was assessed as an index of paracellular permeability. After a 15-minute equilibration, FD4 (0.25 mM) was added to the mucosal side of Ussing chamber-mounted tissues. The FD4 was allowed to equilibrate for 15 minutes, after which 100 ml samples (in triplicate) were collected from the serosal side of tissues at 15-minute intervals and transferred into a 96-well assay plate. The presence of FD4 was assayed by measurement of fluorescence intensity using an fMax fluorescence microplate reader (Molecular Devices, Sunnyvale, CA), and concentrations were determined from standard curves generated by serial dilution of FD4.

2.4.2. In Vivo FD4 Permeability. *In vivo* FD4 intestinal permeability was assessed as previously described [78]. Briefly, food was removed from mice 4 hours prior to the beginning of the study. Mice were gavaged with 30 mg/mouse FD4. Four hours after administration, serum was collected, and fluorescence intensity was assessed as described above.

2.5. Colonic Explant Culture and Cytokine ELISA. Colonic sections were collected and processed as previously described [79]. Colonic tissue samples were weighed, then cut into small fragments and incubated for 24 hours in cell culture media at 37°C, 5% CO₂. Supernatants were collected and stored at -80°C until analysis. IL12p40, IL6, and TNF concentrations were determined in colonic supernatant samples using commercially available sandwich ELISA kits (BD Biosciences, Franklin Lake, NJ), and results were corrected for the amount of tissue in each well.

2.6. Real-Time PCR Array for Mouse Cytokines/Chemokines. RNA was extracted from rinsed colon samples that had been snap frozen in liquid nitrogen and stored at -80°C. Tissues were homogenized, and RNA was extracted using a commercially available kit (RNeasy, Qiagen, Valencia, CA) and was analyzed with a spectrophotometer. RNA was subjected to DNase treatment (RNase-free DNase kit, Qiagen, Valencia, CA) and then was reverse transcribed using a commercially available kit (RT2 First Strand, Qiagen, Valencia, CA) followed by PCR amplification. Samples were analyzed using the RT2 Profiler Array for Mouse Cytokines/Chemokines (Qiagen, Cat number PAMM-150Z, Valencia, CA) according to the manufacturer's instructions in a LightCycler 480 (Roche Life Sciences, Indianapolis, IN) to quantify expression of genes encoding 82 mouse inflammatory cytokines and chemokines. Gene expression was normalized to five housekeeping genes included with each experiment. PCR controls and RT controls were included with each experiment. Data were analyzed, and fold changes were calculated using commercially available software (SA Biosciences, <http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php> website).

2.7. Statistical Analysis. Statistical analysis was accomplished using GraphPad Prism. Groups were compared using a one-way ANOVA, and Bonferroni correction was used to control for multiple comparisons. PCR array data was analyzed using the SA Biosciences PCR array analysis software.

2.8. Ethical Considerations. All animals were housed in accordance with guidelines from the American Association for Laboratory Animal Care and Research Protocols, and experiments were approved by the Institutional Animal Care and Use Committee of North Carolina State University where all animal experiments were performed.

3. Results

3.1. Mast Cells Are Protective against Spontaneous Colitis. To define the role of the mast cell in spontaneous colitis, we examined colonic histopathology in 4 groups of mice on a C57/Bl6 background: wild-type (WT) mice, IL10^{-/-} mice, DKO mice, and DKO mice that were reconstituted with BMMCs. Compared with WT mice and consistent with previous reports, including our own previous study, of IL10^{-/-} mice on the C57Bl/6 background, IL10^{-/-} mice displayed mild, patchy colitis with incomplete penetrance (Figures 1(a), 1(b), and 1(e)) [76, 80, 81]. Compared with IL10^{-/-} mice, DKO mice exhibited more severe colitis by histology (Figures 1(c) and 1(e)), greater colitis scores (colitis scores = 8.0 ± 0.6 versus 12.1 ± 0.7 in IL10^{-/-} and DKO mice, respectively; *p* < 0.001, Figure 1(e)), and mucosal hypertrophy (Figure 1(f)). The colitis in DKO mice was characterized histologically by diffuse inflammatory cell infiltrates (Figure 1(c)), compared to smaller aggregates of lymphoid cells in IL10^{-/-} mice. The inflammation consisted primarily of infiltration of lymphoid cells, with few neutrophils. In some mice, the inflammatory cell infiltrate crossed through the muscularis layer of the intestine (Figure 1(c)). In order to demonstrate that the exacerbation in colitis in DKO mice was mast cell specific, DKO mice were engrafted with BMMCs from WT mice, and colitis was assessed. DKO engrafted with BMMCs reduced histopathology, colitis scores, and mucosal hypertrophy to levels of IL10^{-/-} mice (Figures 1(d)–1(f)).

To confirm that the protective effects of mast cell engraftment were not a result of supplying IL10 derived from engrafted WT BMMCs, we also assessed colitis in DKO mice engrafted with IL10^{-/-} BMMCs (derived from IL10^{-/-} mice). These experiments showed that engraftment of DKO mice with IL10^{-/-} BMMCs ameliorated colitis in a similar manner to WT BMMCs (IL10^{-/-} mean colitis score 3.1 ± 0.3; DKO colitis score 5.3 ± 0.8; and DKO-R^{IL10^{-/-}} colitis score 2.2 ± 0.6; *p* < 0.005), overall indicating that mast cells' protective effects are via a mechanism independent of IL10 secretion (Figure 2).

3.2. Intestinal Permeability Is Elevated in DKO Mice and Is Reversed by Systemic Reconstitution of Bone Marrow-Derived Mast Cells. Given that intestinal permeability is a central mechanism driving intestinal inflammation in colitis models, we next assessed the impact of mast cell deficiency




FIGURE 2: Mast cell-mediated protection against colitis is not IL10-dependent. Reconstitution of DKO mice with IL10^{-/-} bone marrow-derived mast cells (DKO-R^{IL10^{-/-}}) prevents colitis, similar to reconstitution with wild-type mast cells. IL10^{-/-}: $n = 11$; DKO: $n = 11$; DKO-R^{IL10^{-/-}}: $n = 8$. ** $p < 0.01$.

on intestinal barrier function in IL10^{-/-} and DKO mice. Using a FD4 oral gavage method to assess in vivo intestinal permeability, we showed a trend ($p = 0.10$) for elevated intestinal permeability in DKO mice (Figure 3(a)) compared with IL10^{-/-} mice. Further, we assessed intestinal permeability on isolated small intestinal and distal colon segments on Ussing chambers. Consistent with the worsened colitis, DKO mice had significantly increased intestinal permeability (2.7 ± 0.6 ng/min) compared to IL10^{-/-} mice (1.1 ± 0.2 ng/min) (Figure 3(b)). Compared with DKO mice, DKO mice engrafted with BMMCs exhibited a significant reduction in intestinal permeability to levels similar to IL10^{-/-} mice.

3.3. Influence of Mast Cell Deficiency on Proinflammatory Cytokine Production in IL10^{-/-} Model of Colitis. The spontaneous production of proinflammatory cytokine was measured via ELISA in colonic explant supernatants. Compared with IL10^{-/-} mice, DKO had significantly elevated spontaneous colonic production of IL12p40 (4.6 ± 0.6 pg/ml/mg versus 9.7 ± 2.2 pg/ml/mg; $p < 0.05$) and TNF (2.8 ± 0.3 pg/ml/mg versus 5.3 ± 0.7 pg/ml/mg; $p < 0.005$) (Figures 4(a) and 4(b)). Engraftment of DKO mice with wild-type BMMCs ameliorated the increased TNF but not IL12p40. IL6 levels were similar between IL10^{-/-}, DKO, and engrafted DKO mice (Figure 4(c)). Engraftment of DKO mice with IL10^{-/-} BMMCs ameliorated increased TNF, similar to those engrafted with wild-type BMMCs (Figure 4(d)).

3.4. Mast Cell Deficiency and Reconstitution in IL10^{-/-} Associated Colitis Drive the Gene Expression of an Array of Colonic Mucosal Cytokine and Chemokines. To assess the effect of mast cell deficiency on global cytokine regulation, a real-time PCR array assessing 84 cytokines and chemokines was performed on colon mucosal samples from IL10^{-/-} and DKO mice. Comparisons between IL10^{-/-} and DKO mice demonstrated that lack of mast cells in DKO mice produced a large number of perturbations in cytokines and chemokines (Figure 5(a)) which were largely restored to IL10^{-/-} levels in

DKO mice engrafted with mast cells (Figure 5(b)). Results of the cytokine alterations are displayed in Table 1. Specifically, gene expression of anti-inflammatory mediators including *tgfb* and bone morphogenetic proteins (BMPs) 2, 4, and 7 was significantly decreased in DKO mice compared with IL10^{-/-} mice and was rescued by systemic reconstitution of DKO mice with bone marrow-derived mast cells (Table 1 and Figure 6), thus demonstrating a direct role of mast cells in modulating *bmp* genes. Genes that were most highly upregulated in DKO mice were *CCl5* (by 5.19-fold), *Cd40lg* (by 2.54-fold), and *Cxcl9* (by 5.89-fold).

4. Discussion

The results from this study highlight a novel protective role for mast cells in a spontaneous, chronic model of colitis, in the IL10^{-/-} mouse. While the present study confirms previous reports of heightened colitis in DKO mice [45, 46], the amelioration of the colitis with systemic mast cell engraftment in DKO mice in the present study provided a definitive anti-inflammatory role for mast cells in spontaneous, chronic colitis.

Here, we demonstrated that engraftment of DKO mice with either WT or IL10^{-/-} BMMCs resulted in comparable anti-inflammatory effects, confirming that mast cell-specific IL10 was not the major anti-inflammatory mechanism. TNF is an established mediator of inflammation in the IL10^{-/-} mouse model [82] and in human IBD, in which anti-TNF monoclonal antibodies are a clinical mainstay [82, 83]. In the present study, DKO mice had elevated colonic production of TNF and histologic colitis scores that were restored to IL10^{-/-} levels with systemic reconstitution of DKO mice with BMMCs. However, mast cell reconstitution did not reduce the elevated IL6 or IL12p40, indicating that mast cells may be specifically regulating specific cytokines and (or) proinflammatory mediators to dampen colitis. The mechanism by which mast cells dampen colitis is unknown, but that ability of mast cells to suppress immune responses is well established. There are several lines of evidence that mast cells perform important immunoregulatory functions. Mast cells control T cell polarization by affecting cytokine production from other antigen-presenting cells. For example, mast cell mediators including histamine and PGD2 suppress production of IL12 from dendritic cells in vitro [84, 85]. This effect can alter T cell polarization and redirect immune responses. Mast cells also have direct effects on T cells, such as induction of T regulatory cells, which suppress inflammation [51–53, 86]. In a model of graft-versus-host disease, mast cells are essential for maintaining tolerance and preventing graft rejection via induction of T regulatory cells as well as via an unknown mechanism independent of T regulatory cells [51, 87]. Additionally, mast cell-induced T regulatory cells help to suppress inflammation in a model of allergic airway disease [88]. Mast cell mediators contained in their granules also have anti-inflammatory effects. For example, mast cell proteases, such as tryptase and chymase, degrade proinflammatory cytokines and alarmins, which results in an immunoregulatory effect [89–92]. Heparin, another mast cell mediator, has powerful anti-inflammatory




FIGURE 3: DKO mice have increased intestinal permeability that is ameliorated by reconstitution of bone marrow-derived mast cells. (a) In vivo intestinal permeability in IL10^{-/-} and DKO mice (n = 3–5 per group). (b) FD4 permeability across distal colonic mucosa mounted on Ussing chambers. IL10^{-/-}: n = 23; DKO: n = 24; DKO-R^{IL10^{-/-}}: n = 10. *p < 0.05.




FIGURE 4: Spontaneous colonic cytokine production. (a) TNF is increased in DKO mice compared to IL10^{-/-} and is restored to baseline in DKO mice that are reconstituted with BMMCs. (b) IL12p40 is increased in DKO mice compared to IL10^{-/-} but is unaffected by BMMC reconstitution. (c) Colonic IL6 is similar between IL10^{-/-}, DKO, and DKO mice reconstituted with BMMCs. (d) TNF is also restored to baseline in DKO mice reconstituted with IL10^{-/-} BMMCs compared to DKO mice. IL10^{-/-}: n = 25; DKO: n = 25; DKO-rMC: n = 13. *p < 0.05, **p < 0.01.




FIGURE 5: Mast cell deficiency in colitis results in dysregulation of many cytokines and chemokines. (a) Scatter plot representation of average fold change of 84 different cytokine and chemokine genes in $IL10^{-/-}$ compared to DKO mice from RNA extracted from whole colon. Dots above the lines are higher in DKO than in $IL10^{-/-}$ mice, and dots below the line are greater than 2-fold decreased in DKO compared to $IL10^{-/-}$ mice. (b) Reconstitution of DKO mice with BMMCs ameliorates the alteration of cytokines. Represents averaged fold change values in $n = 5$ mice per group.

effects. Heparin binds leukocyte and platelet selectins and downregulates intercellular adhesion molecule-1 (ICAM-1), preventing leukocyte migration to target tissues [93–95], and also downregulates proinflammatory cytokine expression in a process that requires its sulfate groups [96]. Mast cells can also have immunoregulatory roles by limiting pathogenic infections. Mast cells are critical for induction of protective immune responses against viral, bacterial, and parasitic pathogens. Mast cells are critical in the recruitment of neutrophils and enhance resistance to bacterial pathogens including *Klebsiella pneumonia* and *Mycoplasma pneumonia* [62, 97–99], and in the absence of mast cells, pathogen clearance in the urinary bladder is impaired [100]. Lastly, mast cells are important for tissue healing; mast cell-deficient mice have delayed wound healing compared to controls [55, 101]. Mast cells play important functions in each of the three stages of wound healing, including recruitment of neutrophils to the wound during the inflammatory phase [101, 102], stimulation of fibroblasts during the proliferative phase [103], and promoting tissue granulation, cell migration, and angiogenesis during the remodeling phase [104, 105]. Mast cell-derived proteases have been shown to degrade TNF and inflammation [51, 89].

We had hypothesized that the cytokine/chemokine array would reveal skewing toward a so-called Th1 or Th17 cytokine profile, with decreases in the Th2-type cytokines that are classically thought of as being present in mast cell activation, such as IL4 and IL5. Surprisingly, these cytokines were not significantly altered in mast cell deficiency, and a strongly Th1 or Th17 profile was not evident. Instead, we were able to identify particular mediators that were most impacted by mast cell deficiency in the setting of colitis.

Intestinal barrier dysfunction is an important mechanism in the pathogenesis of inflammation in IBD. In the present study, DKO mice exhibited increased intestinal permeability compared to $IL10^{-/-}$ mice which has been reported previously [45]. Given that mast cell mediators such as proteases and TNF are well-known to directly increase intestinal permeability [33, 59, 60, 106, 107], the increased permeability in DKO mice is likely secondary to the increased severity of DKO colitis. Mast cell reconstitution suppressed colitis and reduced intestinal permeability, further supporting the indirect effect of mast cells on intestinal permeability in this model.

A prominent histopathological finding associated with exacerbated colitis in DKO mice was the pronounced increase in colonic mucosal height. The etiology of mucosal hypertrophy in conjunction with colitis is unknown but is a common finding that increases with colitis severity. Mucosal heights in DKO mice were restored to $IL10^{-/-}$ levels upon mast cell reconstitution, demonstrating that mast cells were important in the resolution of mucosal hypertrophy.

While numerous cytokines and chemokines were dysregulated in DKO mice and restored by mast cell reconstitution as assessed by the cytokine array, some of the most significantly altered genes were the BMP proteins. BMP-2, -4, and -6 were all significantly decreased in DKO mice compared to $IL10^{-/-}$. BMP proteins have an established role as modulators of inflammation in many organs. BMP-2, -4, and -7 have been demonstrated to have anti-inflammatory activity in the stomach of mice, and BMP-6 and -7 are protective in renal fibrosis. In line with the present study, BMP7 was shown to exert an anti-inflammatory effect in chemical colitis models [108, 109]. The anti-inflammatory mechanism of the BMPs is not completely understood but has been demonstrated to decrease proliferation in the Jurkat T cell line and to polarize

TABLE 1: Mast cell deficiency results in dysregulation of many different cytokines and chemokines. Fold change and p value of DKO and DKO-rMC mice compared to IL10^{-/-}. Significantly upregulated genes and downregulated genes indicated by bold and italic font, respectively ($p = \leq 0.1$).

	Fold change and p value compared to IL10 DKO		Fold change and p value compared to IL10 DKO-rMC	
	Fold change	p value	Fold change	p value
<i>Adipoq</i>	0.93	0.605923	0.44	0.12537
<i>Bmp2</i>	0.36	0.00275	0.43	0.00352
<i>Bmp4</i>	0.47	0.003545	0.78	0.08664
<i>Bmp6</i>	0.38	0.027679	0.71	0.12534
<i>Bmp7</i>	0.55	0.0662	0.77	0.13341
<i>Ccl1</i>	2.3	0.06215	1.71	0.20753
<i>Ccl11</i>	0.54	0.157722	0.79	0.31294
<i>Ccl12</i>	0.46	0.020304	1.11	0.57195
<i>Ccl17</i>	1.12	0.862792	1.05	0.85839
<i>Ccl19</i>	1.4	0.281436	1.24	0.4384
<i>Ccl2</i>	1.46	0.268872	1.33	0.25702
<i>Ccl20</i>	0.84	0.90886	1.09	0.73897
<i>Ccl22</i>	1.23	0.36045	0.79	0.52381
<i>Ccl24</i>	0.86	0.287519	0.55	0.02211
<i>Ccl3</i>	2.5	0.304203	1.62	0.10923
<i>Ccl4</i>	3.6	0.132224	2.05	0.00244
<i>Ccl5</i>	5.19	0.059787	2.87	0.02972
<i>Ccl7</i>	1.27	0.259336	1.22	0.24594
<i>Cd40lg</i>	2.54	0.035975	2.89	0.01671
<i>Cd70</i>	0.94	0.73583	0.74	0.21501
<i>Cntf</i>	1.05	0.869816	0.79	0.11255
<i>Csf1</i>	0.54	0.011483	0.66	0.10244
<i>Csf2</i>	1.77	0.337615	1.28	0.73852
<i>Csf3</i>	1.93	0.18316	0.95	0.98266
<i>Ctf1</i>	0.49	0.131314	1.13	0.73413
<i>Cx3cl1</i>	0.57	0.024194	0.69	0.14404
<i>Cxcl1</i>	2.65	0.164314	1.48	0.2263
<i>Cxcl10</i>	1.69	0.232777	1.05	0.94321
<i>Cxcl11</i>	1.39	0.368579	0.96	0.96597
<i>Cxcl12</i>	0.44	0.009886	0.71	0.07872
<i>Cxcl13</i>	1.31	0.421716	1.09	0.73564
<i>Cxcl16</i>	1.02	0.830846	0.89	0.42328
<i>Cxcl3</i>	7.7	0.169696	0.95	0.91528
<i>Cxcl5</i>	3.37	0.212199	0.94	0.88692
<i>Cxcl9</i>	5.89	0.078554	3.3	0.06285
<i>Fasl</i>	3.09	0.119071	2.03	0.04219
<i>Gpi1</i>	1.07	0.640631	1.02	0.97433
<i>Hc</i>	0.75	0.681503	1.62	0.1135
<i>Ifna2</i>	0.93	0.605923	0.44	0.12537
<i>Ifng</i>	5.15	0.143744	2.21	0.13276
<i>Il10</i>	0.93	0.605923	0.44	0.12537
<i>Il11</i>	2.39	0.165436	1	0.82803
<i>Il12a</i>	0.54	0.098954	0.61	0.09123
<i>Il12b</i>	1.47	0.256595	1.62	0.12956

TABLE 1: Continued.

	Fold change and p value compared to IL10 DKO		Fold change and p value compared to IL10 DKO-rMC	
	Fold change	p value	Fold change	p value
<i>Il13</i>	1.09	0.651106	1	0.99484
<i>Il15</i>	0.53	0.016916	0.73	0.07861
<i>Il16</i>	1.01	0.896996	0.56	0.04287
<i>Il17a</i>	1.12	0.484613	0.35	0.08594
<i>Il17f</i>	0.68	0.282624	0.55	0.00207
<i>Il18</i>	0.46	0.070874	0.87	0.26885
<i>Il1a</i>	3.9	0.220118	0.9	0.65997
<i>Il1b</i>	3.96	0.172113	1.26	0.38028
<i>Il1rn</i>	0.7	0.006867	0.73	0.03971
<i>Il2</i>	0.94	0.639082	0.48	0.13164
<i>Il21</i>	1.6	0.306708	0.44	0.12537
<i>Il22</i>	1.87	0.268256	0.54	0.12908
<i>Il23a</i>	0.8	0.611696	0.89	0.47794
<i>Il24</i>	1.45	0.684595	0.47	0.13168
<i>Il27</i>	1.45	0.322021	1.28	0.68824
<i>Il3</i>	1.06	0.871143	0.44	0.12537
<i>Il4</i>	1.67	0.323998	2.15	0.02924
<i>Il5</i>	0.73	0.547827	0.66	0.31967
<i>Il6</i>	3.97	0.227976	1.21	0.40714
<i>Il7</i>	0.48	0.180451	0.68	0.13566
<i>Il9</i>	0.93	0.605923	0.55	0.16928
<i>Lif</i>	1.11	0.576603	0.51	0.01984
<i>Lta</i>	0.65	0.44487	0.55	0.6218
<i>Ltb</i>	1.55	0.23314	0.83	0.91681
<i>Mif</i>	1.17	0.107953	1.18	0.29987
<i>Mstn</i>	1.13	0.736482	0.59	0.21285
<i>Nodal</i>	0.93	0.605923	0.52	0.15365
<i>Osm</i>	5.53	0.119627	1.56	0.12463
<i>Pf4</i>	0.47	0.030614	0.63	0.05057
<i>Ppbp</i>	1.14	0.986882	1.54	0.55059
<i>Spp1</i>	4.12	0.261256	1.77	0.93377
<i>Tgfb2</i>	0.51	0.048987	0.77	0.12043
<i>Thpo</i>	1.11	0.432272	1	0.80533
<i>Tnf</i>	2.54	0.151012	1.3	0.2214
<i>Tnfrsf11b</i>	0.91	0.948453	0.92	0.89644
<i>Tnfsf10</i>	1.16	0.779851	1.05	0.97127
<i>Tnfsf11</i>	2.2	0.211322	0.96	0.64542
<i>Tnfsf13b</i>	0.92	0.651414	0.93	0.44799
<i>Vegfa</i>	1.12	0.747986	0.92	0.55534
<i>Xcl1</i>	1.1	0.9224	1.28	0.48461

monocytes towards M2 macrophages [110–112]. Given that the mast cell-deficient DKO mice exhibited suppressed BMP genes, which were restored with mast cell reconstitution, it is demonstrated that mast cells have a major influence on BMP gene transcription which could be a potential mechanism by which mast cells exert anti-




FIGURE 6: Relative expression of *bmp* genes and *tgfb* genes in colonic mucosa as influenced by mast cell deficiency and systemic reconstitution. Genes are expressed relative to IL10^{-/-} mice values as described in the PCR array material and methods.

inflammatory mechanisms. More definitive studies are required to establish this link.

5. Conclusions

In summary, we have demonstrated that mast cells have a key protective role in chronic spontaneous colitis. This finding is in contrast to models of chemical colitis, demonstrating that mast cells can impart protective properties during colitis in the IL10^{-/-} model. One explanation for the divergent effects of mast cells between chemical colitis and the IL10^{-/-} model is that chemical colitis models are acute (days) or subacute (weeks) disease models, while the IL10^{-/-} model more closely recapitulates the chronic, progressive, spontaneous onset of naturally occurring IBD with chronic changes to the intestinal microbiota. Therefore, consistent with reports in other body systems, it seems that while mast cells have deleterious effects in the acute or subacute setting, they have beneficial roles in chronic inflammatory diseases, potentially due to their effects that promote healing [113]. Therefore, given that naturally occurring IBD is a spontaneous, chronic disease with a slow onset, the current work represents a paradigm shift that may more accurately recapitulate the role of the mast cell in naturally occurring disease and thus direct therapeutic interventions towards mast cell activation versus mast cell blockade.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article. Dr. A. J. Moeser is the Matilda R. Wilson endowed chair in the College of Veterinary Medicine at Michigan State University.

Acknowledgments

Dr. E. M. Lennon was supported by the Ruth L. Kirschstein National Research Service Award T32 OD011130 as part of North Carolina State University's Comparative Medicine and Translational Research Training Program. This work was supported by the U.S. National Institutes of Health K01 OD019729 (to E. M. Lennon), R01 HD072968 (to A. J. Moeser), K08 DK097462 (to A. J. Moeser), and R03 DK097462 (to A. J. Moeser).

Supplementary Materials

Histological grading criteria used for determination of colitis scores. (*Supplementary Materials*)

References

- [1] L. A. Graff, J. R. Walker, and C. N. Bernstein, "Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management," *Inflammatory Bowel Diseases*, vol. 15, no. 7, pp. 1105–1118, 2009.
- [2] L. M. Lix, L. A. Graff, J. R. Walker et al., "Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease," *Inflammatory Bowel Diseases*, vol. 14, no. 11, pp. 1575–1584, 2008.
- [3] G. Arora, G. Singh, S. Vadhavkar et al., "Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study," *Digestive Diseases and Sciences*, vol. 55, no. 6, pp. 1689–1695, 2010.
- [4] H. U. De Schepper, J. G. De man, T. G. Moreels, P. A. Pelckmans, and B. Y. De winter, "Review article:

- gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms," *Alimentary Pharmacology & Therapeutics*, vol. 27, no. 8, pp. 621–637, 2008.
- [5] A. Basson, A. Trotter, A. Rodriguez-Palacios, and F. Cominelli, "Mucosal interactions between genetics, diet, and microbiome in inflammatory bowel disease," *Frontiers in Immunology*, vol. 7, 2016.
- [6] R. B. Sartor, "Microbial influences in inflammatory bowel diseases," *Gastroenterology*, vol. 134, no. 2, pp. 577–594, 2008.
- [7] R. B. Sartor, "Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis," *Nature Clinical Practice. Gastroenterology & Hepatology*, vol. 3, no. 7, pp. 390–407, 2006.
- [8] A. M. Bianco, M. Girardelli, and A. Tommasini, "Genetics of inflammatory bowel disease from multifactorial to monogenic forms," *World Journal of Gastroenterology*, vol. 21, no. 43, pp. 12296–12310, 2015.
- [9] J. M. Davies and M. T. Abreu, "The innate immune system and inflammatory bowel disease," *Scandinavian Journal of Gastroenterology*, vol. 50, no. 1, pp. 24–33, 2014.
- [10] T. Karantanos and M. Gazouli, "Inflammatory bowel disease: recent advances on genetics and innate immunity," *Annals of Gastroenterology*, vol. 24, no. 3, pp. 164–172, 2011.
- [11] I. Loddo and C. Romano, "Inflammatory bowel disease: genetics, epigenetics, and pathogenesis," *Frontiers in Immunology*, vol. 6, 2015.
- [12] D. D. Metcalfe, R. Pawankar, S. J. Ackerman et al., "Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases," *World Allergy Organization Journal*, vol. 9, no. 1, p. 7, 2016.
- [13] B. Kratzer and W. F. Pickl, "Years in review: recent progress in cellular allergology," *International Archives of Allergy and Immunology*, vol. 169, no. 1, pp. 1–12, 2016.
- [14] P. Lieberman and L. H. Garvey, "Mast cells and anaphylaxis," *Current Allergy and Asthma Reports*, vol. 16, no. 3, p. 20, 2016.
- [15] T. King, W. Biddle, P. Bhatia, J. Moore, and P. B. Miner Jr, "Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis," *Digestive Diseases and Sciences*, vol. 37, no. 4, pp. 490–495, 1992.
- [16] Y. Sasaki, M. Tanaka, and H. Kudo, "Differentiation between ulcerative colitis and Crohn's disease by a quantitative immunohistochemical evaluation of T lymphocytes, neutrophils, histiocytes and mast cells," *Pathology International*, vol. 52, no. 4, pp. 277–285, 2002.
- [17] A. M. Dvorak, R. A. Monahan, J. E. Osage, and G. R. Dickersin, "Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature," *Human Pathology*, vol. 11, no. 6, pp. 606–619, 1980.
- [18] Y. Nishida, K. Murase, H. Isomoto et al., "Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease," *Hepato-Gastroenterology*, vol. 49, no. 45, pp. 678–682, 2002.
- [19] H. Nolte, N. Spjeldnaes, A. Kruse, and B. Windelborg, "Histamine release from gut mast cells from patients with inflammatory bowel diseases," *Gut*, vol. 31, no. 7, pp. 791–794, 1990.
- [20] A. M. Dvorak, R. S. McLeod, A. Onderdonk et al., "Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo," *International Archives of Allergy and Immunology*, vol. 99, no. 1, pp. 74–83, 2004.
- [21] C. M. Gelbmann, S. Mestermann, V. Gross, M. Kollinger, J. Scholmerich, and W. Falk, "Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin," *Gut*, vol. 45, no. 2, pp. 210–217, 1999.
- [22] A. Andoh, Y. Deguchi, O. Inatomi et al., "Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease," *Oncology Reports*, vol. 16, no. 1, pp. 103–107, 2006.
- [23] M. Vivinus-Nébot, G. Frin-Mathy, H. Bziouche et al., "Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation," *Gut*, vol. 63, no. 5, pp. 744–752, 2014.
- [24] Y. Kurashima, T. Amiya, T. Nochi et al., "Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors," *Nature Communications*, vol. 3, no. 1, p. 1034, 2012.
- [25] C. C. Fox, A. J. Lazenby, W. C. Moore, J. H. Yardley, T. M. Bayless, and L. M. Lichtenstein, "Enhancement of human intestinal mast cell mediator release in active ulcerative colitis," *Gastroenterology*, vol. 99, no. 1, pp. 119–124, 1990.
- [26] M. Raithel, S. Winterkamp, A. Pacurar, P. Ulrich, J. Hochberger, and E. G. Hahn, "Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease," *Scandinavian Journal of Gastroenterology*, vol. 36, no. 2, pp. 174–179, 2001.
- [27] L. Knutson, Ö. Ahrenstedt, B. Odland, and R. Hällgren, "The jejunal secretion of histamine is increased in active Crohn's disease," *Gastroenterology*, vol. 98, no. 4, pp. 849–854, 1990.
- [28] M. Raithel, H. T. Schneider, and E. G. Hahn, "Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease," *Scandinavian Journal of Gastroenterology*, vol. 34, no. 5, pp. 496–503, 1999.
- [29] S. Winterkamp, M. Weidenhiller, P. Otte et al., "Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease," *The American Journal of Gastroenterology*, vol. 97, no. 12, pp. 3071–3077, 2002.
- [30] M. J. Hamilton, M. J. Sinnamon, G. D. Lyng et al., "Essential role for mast cell tryptase in acute experimental colitis," *Proceedings of the National Academy of Sciences*, vol. 108, no. 1, pp. 290–295, 2011.
- [31] M. J. Hamilton, S. M. Frei, and R. L. Stevens, "The multifaceted mast cell in inflammatory bowel disease," *Inflammatory Bowel Diseases*, vol. 20, no. 12, pp. 2364–2378, 2014.
- [32] M. M. Wouters, M. Vicario, and J. Santos, "The role of mast cells in functional GI disorders," *Gut*, vol. 65, no. 1, pp. 155–168, 2015.
- [33] J. Santos, P. C. Yang, J. D. Söderholm, M. Benjamin, and M. H. Perdue, "Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat," *Gut*, vol. 48, no. 5, pp. 630–636, 2001.
- [34] G. Boeckxstaens, "Mast cells and inflammatory bowel disease," *Current Opinion in Pharmacology*, vol. 25, pp. 45–49, 2015.
- [35] Y. Iba, Y. Sugimoto, and C. Kamei, "Participation of mast cells in colitis inflammation induced by dextran sulfate

- sodium," *Methods and Findings in Experimental and Clinical Pharmacology*, vol. 24, no. 1, pp. 15–18, 2002.
- [36] Y. Araki, A. Andoh, Y. Fujiyama, and T. Bamba, "Development of dextran sulphate sodium-induced experimental colitis is suppressed in genetically mast cell-deficient Ws/Ws rats," *Clinical and Experimental Immunology*, vol. 119, no. 2, pp. 264–269, 2000.
- [37] R. Eliakim, F. Karmeli, E. Okon, and D. Rachmilewitz, "Ketotifen effectively prevents mucosal damage in experimental colitis," *Gut*, vol. 33, no. 11, pp. 1498–1503, 1992.
- [38] E. Y. Cho, S. C. Choi, S. H. Lee et al., "Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis," *International Immunopharmacology*, vol. 11, no. 4, pp. 412–417, 2011.
- [39] Y. Isozaki, N. Yoshida, M. Kuroda et al., "Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis," *Scandinavian Journal of Gastroenterology*, vol. 41, no. 8, pp. 944–953, 2009.
- [40] K. Ishida, S. Takai, M. Murano et al., "Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 324, no. 2, pp. 422–426, 2008.
- [41] A. Rijniense, A. S. Koster, F. P. Nijkamp, and A. D. Kraneveld, "Critical role for mast cells in the pathogenesis of 2,4-dinitrobenzene-induced murine colonic hypersensitivity reaction," *Journal of Immunology*, vol. 176, no. 7, pp. 4375–4384, 2006.
- [42] K. W. Chin and K. E. Barrett, "Mast cells are not essential to inflammation in murine model of colitis," *Digestive Diseases and Sciences*, vol. 39, no. 3, pp. 513–525, 1994.
- [43] Y. Iba, Y. Sugimoto, C. Kamei, and T. Masukawa, "Possible role of mucosal mast cells in the recovery process of colitis induced by dextran sulfate sodium in rats," *International Immunopharmacology*, vol. 3, no. 4, pp. 485–491, 2003.
- [44] A. Rigoni, L. Bongiovanni, A. Burocchi et al., "Mast cells infiltrating inflamed or transformed gut alternatively sustain mucosal healing or tumor growth," *Cancer Research*, vol. 75, no. 18, pp. 3760–3770, 2015.
- [45] M. Chichlowski, G. S. Westwood, S. N. Abraham, and L. P. Hale, "Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice," *PLoS One*, vol. 5, no. 8, article e12220, 2010.
- [46] H. Zhang, Y. Xue, H. Wang et al., "Mast cell deficiency exacerbates inflammatory bowel symptoms in interleukin-10-deficient mice," *World Journal of Gastroenterology*, vol. 20, no. 27, pp. 9106–9115, 2014.
- [47] L. L. Reber, R. Sibilano, K. Mukai, and S. J. Galli, "Potential effector and immunoregulatory functions of mast cells in mucosal immunity," *Mucosal Immunology*, vol. 8, no. 3, pp. 444–463, 2015.
- [48] T. C. Theoharides, K. D. Alysandratos, A. Angelidou et al., "Mast cells and inflammation," *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1822, no. 1, pp. 21–33, 2012.
- [49] V. C. de Vries, R. Elgueta, D. M. Lee, and R. J. Noelle, "Mast cell protease 6 is required for allograft tolerance," *Transplantation Proceedings*, vol. 42, no. 7, pp. 2759–2762, 2010.
- [50] V. C. de Vries, K. Pino-Lagos, E. C. Nowak, K. A. Bennett, C. Oliva, and R. J. Noelle, "Mast cells condition dendritic cells to mediate allograft tolerance," *Immunity*, vol. 35, no. 4, pp. 550–561, 2011.
- [51] L. F. Lu, E. F. Lind, D. C. Gondek et al., "Mast cells are essential intermediaries in regulatory T-cell tolerance," *Nature*, vol. 442, no. 7106, pp. 997–1002, 2006.
- [52] W. Zhang, K. Wu, W. He et al., "Transforming growth factor beta 1 plays an important role in inducing CD4(+)CD25(+)forhead box P3(+) regulatory T cells by mast cells," *Clinical & Experimental Immunology*, vol. 161, no. 3, pp. 490–496, 2010.
- [53] X. Nie, G. Cai, W. Zhang et al., "Lipopolysaccharide mediated mast cells induce IL-10 producing regulatory T cells through the ICOSL/ICOS axis," *Clinical Immunology*, vol. 142, no. 3, pp. 269–279, 2012.
- [54] H. P. McNeil, R. Adachi, and R. L. Stevens, "Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense," *Journal of Biological Chemistry*, vol. 282, no. 29, pp. 20785–20789, 2007.
- [55] A. Tellechea, E. C. Leal, A. Kafanas et al., "Mast cells regulate wound healing in diabetes," *Diabetes*, vol. 65, no. 7, pp. 2006–2019, 2016.
- [56] N. Sismanopoulos, D. A. Delivanis, K. D. Alysandratos et al., "Mast cells in allergic and inflammatory diseases," *Current Pharmaceutical Design*, vol. 18, no. 16, pp. 2261–2277, 2012.
- [57] A. Niimi, "Cough, asthma, and cysteinyl-leukotrienes," *Pulmonary Pharmacology & Therapeutics*, vol. 26, no. 5, pp. 514–519, 2013.
- [58] E. Bąbólewska, P. Witczak, A. Pietrzak, and E. Brzezińska-Błaszczyk, "Different potency of bacterial antigens TLR2 and TLR4 ligands in stimulating mature mast cells to cysteinyl leukotriene synthesis," *Microbiology and Immunology*, vol. 56, no. 3, pp. 183–190, 2012.
- [59] K. R. Groschwitz, R. Ahrens, H. Osterfeld et al., "Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism," *Proceedings of the National Academy of Sciences*, vol. 106, no. 52, pp. 22381–22386, 2009.
- [60] S. A. Snoek, S. Dhawan, S. H. van Bree et al., "Mast cells trigger epithelial barrier dysfunction, bacterial translocation and postoperative ileus in a mouse model," *Neurogastroenterology & Motility*, vol. 24, no. 2, pp. 172–e91, 2012.
- [61] Y. Kurashima, Y. Goto, and H. Kiyono, "Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation," *European Journal of Immunology*, vol. 43, no. 12, pp. 3108–3115, 2013.
- [62] R. Malaviya, T. Ikeda, E. Ross, and S. N. Abraham, "Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF- α ," *Nature*, vol. 381, no. 6577, pp. 77–80, 1996.
- [63] I. Castagliuolo, B. K. Wershil, K. Karalis, A. Pasha, S. T. Nikulasson, and C. Pothoulakis, "Colonic mucin release in response to immobilization stress is mast cell dependent," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 274, 6 Part 1, pp. G1094–G1100, 1998.
- [64] C. U. Corvera, O. Déry, K. McConalogue et al., "Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2," *Journal of Clinical Investigation*, vol. 100, no. 6, pp. 1383–1393, 1997.
- [65] M. R. Oliver, D. T. Tan, D. R. Kirk, K. P. Rioux, and R. B. Scott, "Colonic and jejunal motor disturbances after colonic

- antigen challenge of sensitized rat," *Gastroenterology*, vol. 112, no. 6, pp. 1996–2005, 1997.
- [66] N. Castex, J. Fioramonti, M. JoséFargeas, J. More, and L. Bueno, "Role of 5-HT₃ receptors and afferent fibers in the effects of mast cell degranulation on colonic motility in rats," *Gastroenterology*, vol. 107, no. 4, pp. 976–984, 1994.
- [67] S. M. Oliveira, C. R. Silva, and J. Ferreira, "Critical role of protease-activated receptor 2 activation by mast cell tryptase in the development of postoperative pain," *Anesthesiology*, vol. 118, no. 3, pp. 679–690, 2013.
- [68] S. M. Oliveira, C. C. Drewes, C. R. Silva et al., "Involvement of mast cells in a mouse model of postoperative pain," *European Journal of Pharmacology*, vol. 672, no. 1–3, pp. 88–95, 2011.
- [69] W. W. Li, T. Z. Guo, D. Y. Liang, Y. Sun, W. S. Kingery, and J. D. Clark, "Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome," *Anesthesiology*, vol. 116, no. 4, pp. 882–895, 2012.
- [70] H. W. Choi, R. Brooking-Dixon, S. Neupane et al., "Salmonella typhimurium impedes innate immunity with a mast-cell-suppressing protein tyrosine phosphatase, SptP," *Immunity*, vol. 39, no. 6, pp. 1108–1120, 2013.
- [71] C. J. Moran, T. D. Walters, C. H. Guo et al., "IL-10R polymorphisms are associated with very-early-onset ulcerative colitis," *Inflammatory Bowel Diseases*, vol. 19, no. 1, pp. 115–123, 2013.
- [72] E. O. Glocker, D. Kotlarz, K. Boztug et al., "Inflammatory bowel disease and mutations affecting the interleukin-10 receptor," *The New England Journal of Medicine*, vol. 361, no. 21, pp. 2033–2045, 2009.
- [73] B. Begue, J. Verdier, F. Rieux-Laucat et al., "Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease," *The American Journal of Gastroenterology*, vol. 106, no. 8, pp. 1544–1555, 2011.
- [74] E. O. Glocker, N. Frede, M. Perro et al., "Infant colitis—it's in the genes," *Lancet*, vol. 376, no. 9748, p. 1272, 2010.
- [75] C. Jin, C. P. Shelburne, G. Li et al., "Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation," *The Journal of Clinical Investigation*, vol. 121, no. 3, pp. 941–955, 2011.
- [76] D. J. Berg, N. Davidson, R. Kühn et al., "Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses," *The Journal of Clinical Investigation*, vol. 98, no. 4, pp. 1010–1020, 1996.
- [77] S. Ayyadurai, A. J. Gibson, S. D'Costa et al., "Frontline science: corticotropin-releasing factor receptor subtype 1 is a critical modulator of mast cell degranulation and stress-induced pathophysiology," *Journal of Leukocyte Biology*, vol. 102, no. 6, pp. 1299–1312, 2017.
- [78] G. T. Furuta, J. R. Turner, C. T. Taylor et al., "Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia," *The Journal of Experimental Medicine*, vol. 193, no. 9, pp. 1027–1034, 2001.
- [79] R. A. F. Hegazi, K. N. Rao, A. Mayle, A. R. Sepulveda, L. E. Otterbein, and S. E. Plevy, "Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway," *The Journal of Experimental Medicine*, vol. 202, no. 12, pp. 1703–1713, 2005.
- [80] G. Büchler, M. L. Wos-Oxley, A. Smoczek et al., "Strain-specific colitis susceptibility in IL10-deficient mice depends on complex gut microbiota-host interactions," *Inflammatory Bowel Diseases*, vol. 18, no. 5, pp. 943–954, 2012.
- [81] E. M. Lennon, N. Maharshak, H. Elloumi, L. Borst, S. E. Plevy, and A. J. Moeser, "Early life stress triggers persistent colonic barrier dysfunction and exacerbates colitis in adult IL-10^{-/-} mice," *Inflammatory Bowel Diseases*, vol. 19, no. 4, pp. 712–719, 2013.
- [82] T. Scheinin, D. M. Butler, F. Salway, B. Scallan, and M. Feldmann, "Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis," *Clinical and Experimental Immunology*, vol. 133, no. 1, pp. 38–43, 2003.
- [83] E. Louis, "Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease," *Digestive Diseases*, vol. 31, no. 2, pp. 207–212, 2013.
- [84] A. Mazzoni, H. A. Young, J. H. Spitzer, A. Visintin, and D. M. Segal, "Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization," *The Journal of Clinical Investigation*, vol. 108, no. 12, pp. 1865–1873, 2001.
- [85] G. Theiner, A. Gessner, and M. B. Lutz, "The mast cell mediator PGD₂ suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo," *Immunobiology*, vol. 211, no. 6–8, pp. 463–472, 2006.
- [86] P. Y. Gan, S. A. Summers, J. D. Ooi et al., "Mast cells contribute to peripheral tolerance and attenuate autoimmune vasculitis," *Journal of the American Society of Nephrology*, vol. 23, no. 12, pp. 1955–1966, 2012.
- [87] D. B. Leveson-Gower, E. I. Segal, J. Kalesnikoff et al., "Mast cells suppress murine GVHD in a mechanism independent of CD4⁺CD25⁺ regulatory T cells," *Blood*, vol. 122, no. 22, pp. 3659–3665, 2013.
- [88] H. Morita, K. Arae, H. Unno et al., "An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers," *Immunity*, vol. 43, no. 1, pp. 175–186, 2015.
- [89] S. Nelissen, T. Vanganswinkel, N. Geurts et al., "Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4," *Neurobiology of Disease*, vol. 62, pp. 260–272, 2014.
- [90] A. Roy, G. Ganesh, H. Sippola et al., "Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation," *The Journal of Biological Chemistry*, vol. 289, no. 1, pp. 237–250, 2014.
- [91] A. M. Piliponsky, C. C. Chen, E. J. Rios et al., "The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis," *The American Journal of Pathology*, vol. 181, no. 3, pp. 875–886, 2012.
- [92] S. Hendrix, P. Kramer, D. Pehl et al., "Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4," *The FASEB Journal*, vol. 27, no. 3, pp. 920–929, 2013.
- [93] R. M. Nelson, O. Cecconi, W. G. Roberts, A. Aruffo, R. J. Linhardt, and M. P. Bevilacqua, "Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation," *Blood*, vol. 82, no. 11, pp. 3253–3258, 1993.
- [94] L. Wang, J. R. Brown, A. Varki, and J. D. Esko, "Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation

- and are mediated by blockade of L- and P-selectins," *The Journal of Clinical Investigation*, vol. 110, no. 1, pp. 127–136, 2002.
- [95] S. J. Miller, A. M. Hoggat, and W. P. Faulk, "Heparin regulates ICAM-1 expression in human endothelial cells: an example of non-cytokine-mediated endothelial activation," *Thrombosis and Haemostasis*, vol. 80, no. 3, pp. 481–487, 1998.
- [96] N. Y. Yi, D. R. Newman, H. Zhang, H. M. Johansson, and P. L. Sannes, "Heparin and LPS-induced COX-2 expression in airway cells: a link between its anti-inflammatory effects and GAG sulfation," *Experimental Lung Research*, vol. 41, no. 9, pp. 499–513, 2015.
- [97] R. E. Sutherland, J. S. Olsen, A. McKinstry, S. A. Villalta, and P. J. Wolters, "Mast cell IL-6 improves survival from *Klebsiella* pneumonia and sepsis by enhancing neutrophil killing," *Journal of Immunology*, vol. 181, no. 8, pp. 5598–5605, 2008.
- [98] S. M. Thakurdas, E. Melicoff, L. Sansores-Garcia et al., "The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections," *The Journal of Biological Chemistry*, vol. 282, no. 29, pp. 20809–20815, 2007.
- [99] X. Xu, D. Zhang, N. Lyubynska et al., "Mast cells protect mice from *Mycoplasma pneumoniae*," *American Journal of Respiratory and Critical Care Medicine*, vol. 173, no. 2, pp. 219–225, 2006.
- [100] C. Y. Chan, A. L. St. John, and S. N. Abraham, "Mast cell interleukin-10 drives localized tolerance in chronic bladder infection," *Immunity*, vol. 38, no. 2, pp. 349–359, 2013.
- [101] K. Weller, K. Foitzik, R. Paus, W. Syska, and M. Maurer, "Mast cells are required for normal healing of skin wounds in mice," *The FASEB Journal*, vol. 20, no. 13, pp. 2366–2368, 2006.
- [102] E. I. Egozi, A. M. Ferreira, A. L. Burns, R. L. Gamelli, and L. A. Dipietro, "Mast cells modulate the inflammatory but not the proliferative response in healing wounds," *Wound Repair and Regeneration*, vol. 11, no. 1, pp. 46–54, 2003.
- [103] Z. Qu, X. Huang, P. Ahmadi et al., "Synthesis of basic fibroblast growth factor by murine mast cells. Regulation by transforming growth factor beta, tumor necrosis factor alpha, and stem cell factor," *International Archives of Allergy and Immunology*, vol. 115, no. 1, pp. 47–54, 1998.
- [104] A. Trautmann, B. Feuerstein, N. Ernst, E. B. Bröcker, and C. E. Klein, "Heterotypic cell-cell adhesion of human mast cells to fibroblasts," *Archives of Dermatological Research*, vol. 289, no. 4, pp. 194–203, 1997.
- [105] G. J. Younan, Y. I. Heit, P. Dastouri et al., "Mast cells are required in the proliferation and remodeling phases of microdeformational wound therapy," *Plastic and Reconstructive Surgery*, vol. 128, no. 6, pp. 649e–658e, 2011.
- [106] C. Jacob, P. C. Yang, D. Darmoul et al., "Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins," *The Journal of Biological Chemistry*, vol. 280, no. 36, pp. 31936–31948, 2005.
- [107] C. Wallon, P. C. Yang, A. V. Keita et al., "Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro," *Gut*, vol. 57, no. 1, pp. 50–58, 2008.
- [108] I. Maric, L. Poljak, S. Zoricic et al., "Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats," *Journal of Cellular Physiology*, vol. 196, no. 2, pp. 258–264, 2003.
- [109] Z. Hao, X. Yang, Y. Lv, S. Li, B. K. Purbey, and H. Su, "Intracolonic administered adeno-associated virus-bone morphogenetic protein-7 ameliorates dextran sulphate sodium-induced acute colitis in rats," *The Journal of Gene Medicine*, vol. 14, no. 7, pp. 482–490, 2012.
- [110] C. Rocher, R. Singla, P. K. Singal, S. Parthasarathy, and D. K. Singla, "Bone morphogenetic protein 7 polarizes THP-1 cells into M2 macrophages," *Canadian Journal of Physiology and Pharmacology*, vol. 90, no. 7, pp. 947–951, 2012.
- [111] D. K. Singla, R. Singla, and J. Wang, "BMP-7 treatment increases M2 macrophage differentiation and reduces inflammation and plaque formation in Apo E^{-/-} mice," *PLoS One*, vol. 11, no. 1, article e0147897, 2016.
- [112] E. A. Sivertsen, K. Huse, M. E. Hystad, C. Kersten, E. B. Smeland, and J. H. Myklebust, "Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells," *European Journal of Immunology*, vol. 37, no. 10, pp. 2937–2948, 2007.
- [113] V. A. Gimenez-Rivera, F. Siebenhaar, C. Zimmermann, H. Siiskonen, M. Metz, and M. Maurer, "Mast cells limit the exacerbation of chronic allergic contact dermatitis in response to repeated allergen exposure," *Journal of Immunology*, vol. 197, no. 11, pp. 4240–4246, 2016.



Hindawi

Submit your manuscripts at
www.hindawi.com

